期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 40, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13046-021-02030-5
关键词
Primary liver cancer; Cellular based immunotherapy; Lymphoid cell; Myeloid cell; Combined immunotherapy
类别
资金
- National Natural Science Foundation of China [82002539]
- Yangfan Project of Shanghai Science and Technology Commission [20YF1443300]
- Natural Science Foundation of Shanghai [19ZR1447700]
- Health System Innovation Project of Shanghai Putuo Science and Technology Commission [PTKWWS201801, PTKWWS201903]
- WBN Hepatology Research Fund of China Hepatitis Prevention and Treatment Foundation [CFHPC2019031]
Cellular based immunotherapy, with its natural advantages in PLC treatment by involving both lymphoid and myeloid cells, is promising. However, there are still obstacles and challenges in PLC treatment that need to be addressed through comprehensive immunotherapeutic approaches.
Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the exploration of novel therapeutic strategies. For most malignancies, including PLC, immune cells play crucial roles in regulating tumor microenvironments and specifically recognizing tumor cells. Therefore, cellular based immunotherapy has its instinctive advantages in PLC therapy as a novel therapeutic strategy. From the active and passive immune perspectives, we introduced the cellular based immunotherapies for PLC in this review, covering both the lymphoid and myeloid cells. Then we briefly review the combined cellular immunotherapeutic approaches and the existing obstacles for PLC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据